| 1 | options | 6,160 |
| 2 | panel-iii | 5 |
| 3 | nanoplatform | 4 |
| 4 | retention/completion | 3 |
| 5 | cyclohexanes | 2 |
| 6 | interventions/treatments | 2 |
| 7 | strongholds | 2 |
| 8 | 159·2 | 1 |
| 9 | 4.2±0.7 | 1 |
| 10 | 71.44±21.98 | 1 |
| 11 | 72.13±33.24 | 1 |
| 12 | abstentions | 1 |
| 13 | addressly | 1 |
| 14 | agents-the | 1 |
| 15 | aglycosylated | 1 |
| 16 | alone.however | 1 |
| 17 | approaches-neodymium-yttrium | 1 |
| 18 | arm. | 1 |
| 19 | arm.secondary | 1 |
| 20 | arsenals | 1 |
| 21 | benefi | 1 |
| 22 | center/halfway | 1 |
| 23 | comparisons.overall | 1 |
| 24 | completion.multi-micronutrient | 1 |
| 25 | contact-the | 1 |
| 26 | difference=-2.56 | 1 |
| 27 | difference=-3.32 | 1 |
| 28 | dropout/participation | 1 |
| 29 | duplicities | 1 |
| 30 | duration-dependant | 1 |
| 31 | effect=3.01 | 1 |
| 32 | effectiveness-i.e. | 1 |
| 33 | entry/attendance | 1 |
| 34 | failure-overall | 1 |
| 35 | failures.however | 1 |
| 36 | goals… | 1 |
| 37 | group.it | 1 |
| 38 | groups-including | 1 |
| 39 | groups-paroxetine-only | 1 |
| 40 | groups-saline | 1 |
| 41 | groups.insulin | 1 |
| 42 | grup | 1 |
| 43 | guideline-papers | 1 |
| 44 | in-hand | 1 |
| 45 | intervention/s | 1 |
| 46 | macrosolute | 1 |
| 47 | modalities-the | 1 |
| 48 | of.56 | 1 |
| 49 | ofamenorrhea | 1 |
| 50 | ofidiopathic | 1 |
| 51 | ofphotoinduced | 1 |
| 52 | ofrftvr | 1 |
| 53 | options.this | 1 |
| 54 | orders-glu-asp-lis | 1 |
| 55 | outcome/improvement | 1 |
| 56 | panel-3 | 1 |
| 57 | paradigms-recovery | 1 |
| 58 | period.bronchial | 1 |
| 59 | periods-if | 1 |
| 60 | plans.there | 1 |
| 61 | procedures-hemostasis | 1 |
| 62 | safety.this | 1 |
| 63 | satisfaction-visual | 1 |
| 64 | schedule.the | 1 |
| 65 | sequencies | 1 |
| 66 | spophyllin | 1 |
| 67 | strategems | 1 |
| 68 | strategies-beta-blockers | 1 |
| 69 | strategy.an | 1 |
| 70 | system-paediatric | 1 |
| 71 | trial-normative | 1 |
| 1 | 159·2 | 1 |
| 2 | 4.2±0.7 | 1 |
| 3 | 71.44±21.98 | 1 |
| 4 | 72.13±33.24 | 1 |
| 5 | abstentions | 1 |
| 6 | addressly | 1 |
| 7 | agents-the | 1 |
| 8 | aglycosylated | 1 |
| 9 | alone.however | 1 |
| 10 | approaches-neodymium-yttrium | 1 |
| 11 | arm. | 1 |
| 12 | arm.secondary | 1 |
| 13 | arsenals | 1 |
| 14 | benefi | 1 |
| 15 | center/halfway | 1 |
| 16 | comparisons.overall | 1 |
| 17 | completion.multi-micronutrient | 1 |
| 18 | contact-the | 1 |
| 19 | cyclohexanes | 2 |
| 20 | difference=-2.56 | 1 |
| 21 | difference=-3.32 | 1 |
| 22 | dropout/participation | 1 |
| 23 | duplicities | 1 |
| 24 | duration-dependant | 1 |
| 25 | effect=3.01 | 1 |
| 26 | effectiveness-i.e. | 1 |
| 27 | entry/attendance | 1 |
| 28 | failure-overall | 1 |
| 29 | failures.however | 1 |
| 30 | goals… | 1 |
| 31 | group.it | 1 |
| 32 | groups-including | 1 |
| 33 | groups-paroxetine-only | 1 |
| 34 | groups-saline | 1 |
| 35 | groups.insulin | 1 |
| 36 | grup | 1 |
| 37 | guideline-papers | 1 |
| 38 | in-hand | 1 |
| 39 | intervention/s | 1 |
| 40 | interventions/treatments | 2 |
| 41 | macrosolute | 1 |
| 42 | modalities-the | 1 |
| 43 | nanoplatform | 4 |
| 44 | of.56 | 1 |
| 45 | ofamenorrhea | 1 |
| 46 | ofidiopathic | 1 |
| 47 | ofphotoinduced | 1 |
| 48 | ofrftvr | 1 |
| 49 | options | 6,160 |
| 50 | options.this | 1 |
| 51 | orders-glu-asp-lis | 1 |
| 52 | outcome/improvement | 1 |
| 53 | panel-3 | 1 |
| 54 | panel-iii | 5 |
| 55 | paradigms-recovery | 1 |
| 56 | period.bronchial | 1 |
| 57 | periods-if | 1 |
| 58 | plans.there | 1 |
| 59 | procedures-hemostasis | 1 |
| 60 | retention/completion | 3 |
| 61 | safety.this | 1 |
| 62 | satisfaction-visual | 1 |
| 63 | schedule.the | 1 |
| 64 | sequencies | 1 |
| 65 | spophyllin | 1 |
| 66 | strategems | 1 |
| 67 | strategies-beta-blockers | 1 |
| 68 | strategy.an | 1 |
| 69 | strongholds | 2 |
| 70 | system-paediatric | 1 |
| 71 | trial-normative | 1 |
| 1 | effectiveness-i.e. | 1 |
| 2 | arm. | 1 |
| 3 | effect=3.01 | 1 |
| 4 | difference=-3.32 | 1 |
| 5 | 159·2 | 1 |
| 6 | panel-3 | 1 |
| 7 | 72.13±33.24 | 1 |
| 8 | difference=-2.56 | 1 |
| 9 | of.56 | 1 |
| 10 | 4.2±0.7 | 1 |
| 11 | 71.44±21.98 | 1 |
| 12 | ofamenorrhea | 1 |
| 13 | ofidiopathic | 1 |
| 14 | system-paediatric | 1 |
| 15 | ofphotoinduced | 1 |
| 16 | aglycosylated | 1 |
| 17 | in-hand | 1 |
| 18 | entry/attendance | 1 |
| 19 | modalities-the | 1 |
| 20 | agents-the | 1 |
| 21 | contact-the | 1 |
| 22 | schedule.the | 1 |
| 23 | groups-saline | 1 |
| 24 | plans.there | 1 |
| 25 | macrosolute | 1 |
| 26 | trial-normative | 1 |
| 27 | periods-if | 1 |
| 28 | groups-including | 1 |
| 29 | benefi | 1 |
| 30 | panel-iii | 5 |
| 31 | period.bronchial | 1 |
| 32 | satisfaction-visual | 1 |
| 33 | failure-overall | 1 |
| 34 | comparisons.overall | 1 |
| 35 | nanoplatform | 4 |
| 36 | approaches-neodymium-yttrium | 1 |
| 37 | strategy.an | 1 |
| 38 | spophyllin | 1 |
| 39 | groups.insulin | 1 |
| 40 | dropout/participation | 1 |
| 41 | retention/completion | 3 |
| 42 | grup | 1 |
| 43 | alone.however | 1 |
| 44 | failures.however | 1 |
| 45 | ofrftvr | 1 |
| 46 | intervention/s | 1 |
| 47 | strongholds | 2 |
| 48 | sequencies | 1 |
| 49 | duplicities | 1 |
| 50 | cyclohexanes | 2 |
| 51 | options.this | 1 |
| 52 | safety.this | 1 |
| 53 | orders-glu-asp-lis | 1 |
| 54 | procedures-hemostasis | 1 |
| 55 | arsenals | 1 |
| 56 | strategems | 1 |
| 57 | abstentions | 1 |
| 58 | options | 6,160 |
| 59 | strategies-beta-blockers | 1 |
| 60 | guideline-papers | 1 |
| 61 | interventions/treatments | 2 |
| 62 | group.it | 1 |
| 63 | duration-dependant | 1 |
| 64 | completion.multi-micronutrient | 1 |
| 65 | outcome/improvement | 1 |
| 66 | center/halfway | 1 |
| 67 | groups-paroxetine-only | 1 |
| 68 | addressly | 1 |
| 69 | arm.secondary | 1 |
| 70 | paradigms-recovery | 1 |
| 71 | goals… | 1 |